The Clinical Utility of Biomarkers in the Management of Pancreatic Adenocarcinoma

Khalid A. Jazieh, Michael B. Foote, Luis A. Diaz

Research output: Contribution to journalArticle

Abstract

Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States and survival rates have seen minimal improvement over the past few decades. Although results are poor, surgical resection is considered the only curative therapeutic intervention for pancreatic cancer, thereby emphasizing the significance of effective diagnostic and prognostic tools to improve outcomes. As such, biomarkers play a promising role in the development of personalized treatments for patients with pancreatic cancer. Prognostic biomarkers, such as serum carbohydrate antigen 19-9 in particular, as well as cancer stem cell markers, provide valuable insight into the biological processes of an individual and their likely course of disease. This, consequently, allows for the assessment of optimal therapeutic intervention. Furthermore, current efforts target putative predictive biomarkers such as BRCA2, PALB2, and SPARC so as to determine their influence on tumor response on targeted therapies. As research progresses, more evidence will provide clinicians with guidelines on the utilization of biomarkers to accurately stage and tailor personalized treatment to the needs of specific patients with pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)67-76
Number of pages10
JournalSeminars in Radiation Oncology
Volume24
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Adenocarcinoma
Pancreatic Neoplasms
Biomarkers
Biological Phenomena
Therapeutics
Neoplastic Stem Cells
Neoplasms
Survival Rate
Carbohydrates
Guidelines
Antigens
Serum
Research

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research
  • Medicine(all)

Cite this

The Clinical Utility of Biomarkers in the Management of Pancreatic Adenocarcinoma. / Jazieh, Khalid A.; Foote, Michael B.; Diaz, Luis A.

In: Seminars in Radiation Oncology, Vol. 24, No. 2, 2014, p. 67-76.

Research output: Contribution to journalArticle

Jazieh, Khalid A. ; Foote, Michael B. ; Diaz, Luis A. / The Clinical Utility of Biomarkers in the Management of Pancreatic Adenocarcinoma. In: Seminars in Radiation Oncology. 2014 ; Vol. 24, No. 2. pp. 67-76.
@article{7603293f5d824a93ba0cf1d48fd1ec58,
title = "The Clinical Utility of Biomarkers in the Management of Pancreatic Adenocarcinoma",
abstract = "Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States and survival rates have seen minimal improvement over the past few decades. Although results are poor, surgical resection is considered the only curative therapeutic intervention for pancreatic cancer, thereby emphasizing the significance of effective diagnostic and prognostic tools to improve outcomes. As such, biomarkers play a promising role in the development of personalized treatments for patients with pancreatic cancer. Prognostic biomarkers, such as serum carbohydrate antigen 19-9 in particular, as well as cancer stem cell markers, provide valuable insight into the biological processes of an individual and their likely course of disease. This, consequently, allows for the assessment of optimal therapeutic intervention. Furthermore, current efforts target putative predictive biomarkers such as BRCA2, PALB2, and SPARC so as to determine their influence on tumor response on targeted therapies. As research progresses, more evidence will provide clinicians with guidelines on the utilization of biomarkers to accurately stage and tailor personalized treatment to the needs of specific patients with pancreatic cancer.",
author = "Jazieh, {Khalid A.} and Foote, {Michael B.} and Diaz, {Luis A.}",
year = "2014",
doi = "10.1016/j.semradonc.2013.11.007",
language = "English (US)",
volume = "24",
pages = "67--76",
journal = "Seminars in Radiation Oncology",
issn = "1053-4296",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - The Clinical Utility of Biomarkers in the Management of Pancreatic Adenocarcinoma

AU - Jazieh, Khalid A.

AU - Foote, Michael B.

AU - Diaz, Luis A.

PY - 2014

Y1 - 2014

N2 - Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States and survival rates have seen minimal improvement over the past few decades. Although results are poor, surgical resection is considered the only curative therapeutic intervention for pancreatic cancer, thereby emphasizing the significance of effective diagnostic and prognostic tools to improve outcomes. As such, biomarkers play a promising role in the development of personalized treatments for patients with pancreatic cancer. Prognostic biomarkers, such as serum carbohydrate antigen 19-9 in particular, as well as cancer stem cell markers, provide valuable insight into the biological processes of an individual and their likely course of disease. This, consequently, allows for the assessment of optimal therapeutic intervention. Furthermore, current efforts target putative predictive biomarkers such as BRCA2, PALB2, and SPARC so as to determine their influence on tumor response on targeted therapies. As research progresses, more evidence will provide clinicians with guidelines on the utilization of biomarkers to accurately stage and tailor personalized treatment to the needs of specific patients with pancreatic cancer.

AB - Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States and survival rates have seen minimal improvement over the past few decades. Although results are poor, surgical resection is considered the only curative therapeutic intervention for pancreatic cancer, thereby emphasizing the significance of effective diagnostic and prognostic tools to improve outcomes. As such, biomarkers play a promising role in the development of personalized treatments for patients with pancreatic cancer. Prognostic biomarkers, such as serum carbohydrate antigen 19-9 in particular, as well as cancer stem cell markers, provide valuable insight into the biological processes of an individual and their likely course of disease. This, consequently, allows for the assessment of optimal therapeutic intervention. Furthermore, current efforts target putative predictive biomarkers such as BRCA2, PALB2, and SPARC so as to determine their influence on tumor response on targeted therapies. As research progresses, more evidence will provide clinicians with guidelines on the utilization of biomarkers to accurately stage and tailor personalized treatment to the needs of specific patients with pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=84895858576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895858576&partnerID=8YFLogxK

U2 - 10.1016/j.semradonc.2013.11.007

DO - 10.1016/j.semradonc.2013.11.007

M3 - Article

C2 - 24635863

AN - SCOPUS:84895858576

VL - 24

SP - 67

EP - 76

JO - Seminars in Radiation Oncology

JF - Seminars in Radiation Oncology

SN - 1053-4296

IS - 2

ER -